

# Stuart W Peltz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6778312/publications.pdf>

Version: 2024-02-01

25  
papers

4,332  
citations

361413

20  
h-index

580821

25  
g-index

25  
all docs

25  
docs citations

25  
times ranked

4615  
citing authors

#	ARTICLE	IF	CITATIONS
1	The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. <i>Virus Research</i> , 2021, 292, 198246.	2.2	53
2	Small molecule splicing modifiers with systemic HTT-lowering activity. <i>Nature Communications</i> , 2021, 12, 7299.	12.8	45
3	Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 973-984.	1.4	41
4	Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 3-16.	4.1	65
5	The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential. <i>PLoS ONE</i> , 2018, 13, e0206158.	2.5	30
6	The nucleoside analog cliticine is a potent and efficacious readthrough agent. <i>Rna</i> , 2017, 23, 567-577.	3.5	31
7	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 1489-1498.	13.7	365
8	Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform. <i>PLoS ONE</i> , 2016, 11, e0168366.	2.5	18
9	Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 296-305.	1.6	16
10	<i>SMN2</i> splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. <i>Science</i> , 2014, 345, 688-693.	12.6	420
11	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 539-547.	10.7	301
12	Ataluren as an Agent for Therapeutic Nonsense Suppression. <i>Annual Review of Medicine</i> , 2013, 64, 407-425.	12.2	160
13	Identification of PTC725, an Orally Bioavailable Small Molecule That Selectively Targets the Hepatitis C Virus NS4B Protein. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3250-3261.	3.2	19
14	Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. <i>Journal of Applied Physiology</i> , 2010, 109, 901-905.	2.5	38
15	Nonsense suppression activity of PTC124 (ataluren). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, E64; author reply E65.	7.1	36
16	Targeting post-transcriptional control for drug discovery. <i>RNA Biology</i> , 2009, 6, 329-334.	3.1	14
17	PTC124 is an orally bioavailable compound that promotes suppression of the human <i>CFTR</i> -G542X nonsense allele in a CF mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 2064-2069.	7.1	233
18	Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single- and Multiple-Dose Administration to Healthy Male and Female Adult Volunteers. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 430-444.	2.0	218

#	ARTICLE	IF	CITATIONS
19	PTC124 targets genetic disorders caused by nonsense mutations. <i>Nature</i> , 2007, 447, 87-91.	27.8	1,007
20	Mining the GEMS â€” a novel platform technology targeting post-transcriptional control mechanisms. <i>Drug Discovery Today</i> , 2007, 12, 553-560.	6.4	14
21	A newly discovered function for RNase L in regulating translation termination. <i>Nature Structural and Molecular Biology</i> , 2005, 12, 505-512.	8.2	70
22	Nonsense-mediated mRNA decay in <i>Saccharomyces cerevisiae</i> . <i>Gene</i> , 2001, 274, 15-25.	2.2	124
23	The cap-to-tail guide to mRNA turnover. <i>Nature Reviews Molecular Cell Biology</i> , 2001, 2, 237-246.	37.0	705
24	The Yeast hnRNP-like Protein Hrp1/Nab4 Marks a Transcript for Nonsense-Mediated mRNA Decay. <i>Molecular Cell</i> , 2000, 5, 489-499.	9.7	145
25	The RNA Binding Protein Pub1 Modulates the Stability of Transcripts Containing Upstream Open Reading Frames. <i>Cell</i> , 2000, 101, 741-751.	28.9	164